PMID- 35138995
OWN - NLM
STAT- MEDLINE
DCOM- 20220304
LR  - 20220501
IS  - 1744-5116 (Electronic)
IS  - 1388-0209 (Print)
IS  - 1388-0209 (Linking)
VI  - 60
IP  - 1
DP  - 2022 Dec
TI  - Jinlida granules ameliorate the high-fat-diet induced liver injury in mice by 
      antagonising hepatocytes pyroptosis.
PG  - 274-281
LID - 10.1080/13880209.2022.2029501 [doi]
AB  - CONTEXT: Jinlida (JLD) as a traditional Chinese medicine formula has been used to 
      treat type 2 diabetes mellitus (T2DM) and studies have shown its anti-obesity 
      effect. OBJECTIVE: To investigate the therapeutic effects of JLD in a mouse model 
      of non-alcoholic fatty liver (NAFL). MATERIALS AND METHODS: C57BL/6J mice were 
      divided into three groups and fed a low-diet diet (LFD), high-fat diet (HFD), or 
      HFD + JLD (3.8 g/kg) for 16 weeks, respectively. The free fatty acids-induced 
      lipotoxicity in HepG2 cells were used to evaluate the anti-pyroptotic effects of 
      JLD. The pharmacological effects of JLD on NAFL were investigated by pathological 
      examination, intraperitoneal glucose and insulin tolerance tests, western 
      blotting, and quantitative real-time PCR. RESULTS: In vivo studies showed that 
      JLD ameliorated HFD-induced liver injury, significantly decreased body weight and 
      enhanced insulin sensitivity and improved glucose tolerance. Furthermore, JLD 
      suppressed both the mRNA expression of caspase-1 (1.58 vs. 2.90), IL-1beta (0.93 vs. 
      3.44) and IL-18 (1.34 vs. 1.60) and protein expression of NLRP3 (2.04 vs. 5.71), 
      pro-caspase-1 (2.68 vs. 4.92) and IL-1beta (1.61 vs. 2.60). In vitro, JLD inhibited 
      the formation of lipid droplets induced by 2 mM FFA (IC(50) = 2.727 mM), reduced 
      the protein expression of NLRP3 (0.74 vs. 2.27), caspase-1 (0.57 vs. 2.68), p20 
      (1.67 vs. 3.33), and IL-1beta (1.44 vs. 2.41), and lowered the ratio of 
      p-IKB-alpha/IKB-alpha (0.47 vs. 2.19). CONCLUSION: JLD has a protective effect against 
      NAFLD, which may be related to its anti-pyroptosis, suggesting that JLD has the 
      potential as a novel agent in the treatment of NAFLD.
FAU - Hao, Yuan-Yuan
AU  - Hao YY
AUID- ORCID: 0000-0001-8573-5433
AD  - College of Integrative Medicine, Hebei University of Chinese Medicine, Hebei, 
      China.
FAU - Cui, Wen-Wen
AU  - Cui WW
AUID- ORCID: 0000-0003-0391-4150
AD  - College of Integrative Medicine, Hebei University of Chinese Medicine, Hebei, 
      China.
AD  - Hebei Yiling Pharmaceutical Research Institute, Hebei, China.
FAU - Gao, Huai-Lin
AU  - Gao HL
AUID- ORCID: 0000-0002-4952-680X
AD  - College of Integrative Medicine, Hebei University of Chinese Medicine, Hebei, 
      China.
AD  - Hebei Yiling Hospital, Hebei, China.
FAU - Wang, Ming-Ye
AU  - Wang MY
AUID- ORCID: 0000-0001-9507-4181
AD  - College of Integrative Medicine, Hebei University of Chinese Medicine, Hebei, 
      China.
FAU - Liu, Yan
AU  - Liu Y
AUID- ORCID: 0000-0002-9592-4710
AD  - Xianghe Hospital of Traditional Chinese Medicine, Hebei, China.
FAU - Li, Cui-Ru
AU  - Li CR
AUID- ORCID: 0000-0001-9896-0904
AD  - College of Integrative Medicine, Hebei University of Chinese Medicine, Hebei, 
      China.
AD  - National Key Laboratory of Luobing Research and Innovative Chinese Medicine, 
      Hebei, China.
FAU - Hou, Yun-Long
AU  - Hou YL
AUID- ORCID: 0000-0002-6989-8221
AD  - College of Integrative Medicine, Hebei University of Chinese Medicine, Hebei, 
      China.
AD  - Hebei Yiling Pharmaceutical Research Institute, Hebei, China.
FAU - Jia, Zhen-Hua
AU  - Jia ZH
AUID- ORCID: 0000-0001-5132-1099
AD  - Hebei Yiling Hospital, Hebei, China.
AD  - National Key Laboratory of Luobing Research and Innovative Chinese Medicine, 
      Hebei, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pharm Biol
JT  - Pharmaceutical biology
JID - 9812552
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (jinlida)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Body Weight/drug effects
MH  - Diet, High-Fat
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Glucose/metabolism
MH  - Hep G2 Cells
MH  - Hepatocytes/*drug effects/pathology
MH  - Humans
MH  - Insulin Resistance
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Non-alcoholic Fatty Liver Disease/*prevention & control
MH  - Pyroptosis/*drug effects
PMC - PMC8843117
OTO - NOTNLM
OT  - HepG2
OT  - NAFL
OT  - pyroptosis pathway
OT  - traditional Chinese medicine
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/02/10 06:00
MHDA- 2022/03/05 06:00
PMCR- 2022/02/09
CRDT- 2022/02/09 17:12
PHST- 2022/02/09 17:12 [entrez]
PHST- 2022/02/10 06:00 [pubmed]
PHST- 2022/03/05 06:00 [medline]
PHST- 2022/02/09 00:00 [pmc-release]
AID - 2029501 [pii]
AID - 10.1080/13880209.2022.2029501 [doi]
PST - ppublish
SO  - Pharm Biol. 2022 Dec;60(1):274-281. doi: 10.1080/13880209.2022.2029501.